ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

JS1-1-01 low-dose group

Its studies are mostly in Depression, led by China Resources Pharmaceutical Group.

Furthest: phase 3, since Mar 16, 20262 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
China Resources Pharmaceutical Group21 open or runningphase 3since Mar 16, 2026Feb 6, 2024Dec 31, 2026phase 3 · NCT07485595

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2024First study: phase 2 study in DepressionFirst studyNCT06259526 · 267 enrolled · China
  2. Mar 16, 2026Phase 3 study in DepressionPhase 3 reachedNCT07485595 · 180 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in DepressionNCT07485595

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07485595Depression · China3Not yet recruitingDec 31, 2026180
NCT06259526Depression · China2CompletedOct 23, 2024267

How it is read

Names in the registry

  • “JS1-1-01 low-dose group”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.